| abstract |
The present invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject, wherein the delivered dose of said lipocalin mutein, or variant or fragment thereof, is from about 0.1mg to about 160mg. The lipocalin mutein, or a variant or fragment thereof, may for example be administered at least once per day, once per day or twice per day. |